Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Elvis Shehu"'
Autor:
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang, Wilfried Passe-Coutrin, Alain Fournier, Yu-Tzu Tai, Kenneth C. Anderson, Dmitri Wiederschain, Keith Bahjat, Francisco J. Adrián, Marielle Chiron
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Upon binding to CD38-expressing MM cells, isatuximab
Externí odkaz:
https://doaj.org/article/c6c673aa2cd34bed8e6c98d6ee4b2379
Autor:
Francisco J. Adrian, Marielle Chiron Blondel, Chen Zhu, Xueyan Chen, Srimathi Srinivasan, Elvis Shehu, Jonathan R. Fromm, Celine Nicolazzi, Gang Zheng, Zhili Song, Anlai Wang
Supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d88bb88858ea1f14c32ea3500bd8f389
https://doi.org/10.1158/1535-7163.22520799
https://doi.org/10.1158/1535-7163.22520799
Autor:
Francisco J. Adrian, Marielle Chiron Blondel, Chen Zhu, Xueyan Chen, Srimathi Srinivasan, Elvis Shehu, Jonathan R. Fromm, Celine Nicolazzi, Gang Zheng, Zhili Song, Anlai Wang
This study reports the pharmacologic effects of isatuximab, a CD38 mAb, on T- and B-cell acute lymphoblastic leukemia (ALL). We analyzed CD38 expression in 50-T-ALL and 50 B-ALL clinical samples, and 16 T-ALL and 11 B-ALL cell lines. We primarily foc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04ecc42ccab581989a39fcfdd73f408f
https://doi.org/10.1158/1535-7163.c.6542781
https://doi.org/10.1158/1535-7163.c.6542781
Autor:
Gang Zheng, Marielle F. Chiron Blondel, Anlai Wang, Xueyan Chen, Srimathi Srinivasan, Elvis Shehu, Zhili Song, Chen Zhu, Céline Nicolazzi, Francisco Adrian, Jonathan R. Fromm
Publikováno v:
Molecular cancer therapeutics. 20(10)
This study reports the pharmacologic effects of isatuximab, a CD38 mAb, on T- and B-cell acute lymphoblastic leukemia (ALL). We analyzed CD38 expression in 50-T-ALL and 50 B-ALL clinical samples, and 16 T-ALL and 11 B-ALL cell lines. We primarily foc
Autor:
Kenneth C. Anderson, Wilfried Passe-Coutrin, Rita Greco, Marielle Chiron, Alain Fournier, Srimathi Srinivasan, Yu-Tzu Tai, Keith Bahjat, Zhili Song, Lan Wu, Francisco Adrian, Zhi-Yong Yang, Guang Yang, Anlai Wang, Joachim Theilhaber, Chen Zhu, Elvis Shehu, Dmitri Wiederschain
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
Frontiers in Immunology
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Upon binding to CD38-expressing MM cells, isatuximab
Autor:
Andrew Scholte, Jinyu Liu, Maria Fitzgerald, Jie Ge, D. Niu, Haibo Liu, Beatriz Ospina, Michael Kothe, Laura Akullian D’Agostino, Joshua Murtie, Gang Zheng, Fangxian Sun, Elvis Shehu, Zhendong Zhu, Mcdonald Joseph John, Matthieu Barrague, Kelly Fahnoe, Darren Harvey, Mark Munson, Zhigang Wang, Jennifer Rocnik, Robert Tjin Tham Sjin, Keli Perron, Alex Dubrovskiy
Publikováno v:
ACS Med Chem Lett
[Image: see text] Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer and is one of the most common forms of cancer worldwide. Aberrant signaling of the FGF19-FGFR4 pathway leads to HCC in mice and is hypothesized to be a d
Autor:
Zhili Song, Rita Greco, Francisco Adrian, Chen Zhu, Dmitri Wiederschain, Anlai Wang, Guang Yang, Daniel Ajona, Bruno Paiva, Joachim Theilhaber, Marielle F. Chiron Blondel, Elvis Shehu
Publikováno v:
Cancer Research. 79:2966-2966
Isatuximab (Isa) is an IgG1 monoclonal antibody (Ab) that specifically recognizes human CD38. Once Isa engages multiple myeloma (MM) cells expressing a high level of CD38, it can induce tumor cell killing via Fc-dependent mechanisms including Ab-depe